Across TCGA pan-cancer cohorts, ANKRD36B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ANKRD36B data layer compared with 27 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ANKRD36B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKRD36B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, BLCA, and SKCM are the cancer types where ANKRD36B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.868	0.629	.005	36	view →
BLCA	OS	Median	III,IV	0.130	0.684	<.001	24	view →
SKCM	DFS	Median	All	0.388	0.622	.040	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ANKRD36B tumor-vs-normal RNA expression · all ANKRD36B data types